Novo Nordisk

The Committee for Medicinal Products for Human Use (CHMP) has issued positive opinion of our higher dose of injectable obesity medicine 7.2 mg Learn more in the press release here: https://lnkd.in/eqU2GN4J #PRESS

We have completed our acquisition of Akero Therapeutics. We're committed to addressing obesity, diabetes, and their related comorbidities. By combining our strengths, we can accelerate progress for people living with MASH and move closer to delivering much-needed therapeutic options.   A warm welcome to our new colleagues! Learn more in the press release here https://lnkd.in/enJf2ksh #PRESS

Out of 45,000 online pharmacies worldwide, 95% are illegal and may harm your health👇 These dangerous products can contain wrong ingredients, incorrect doses, or even harmful substances. It’s important to ensure patients are getting authentic medicines from trusted sources.

Inspired to take action.   Throughout November, colleagues hosted events, shared and listened to powerful stories, and joined fundraising walks - all in support of the diabetes community 💙 Let’s continue to raise diabetes awareness and work towards a healthier future for everyone.   How did you mark #DiabetesAwarenessMonth? Share your moments in the comments 👇

Over 589 million people live with diabetes – more than 90% have type 2. Type 2 diabetes can quietly affect the heart, kidneys, nerves, liver and eyes, often before symptoms appear.

We're filing for FDA approval of a higher dose of injectable obesity medicine 7.2 mg. Learn more in our press release here https://lnkd.in/dKVmTFFv #PRESS

Our phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. Hear Martin Holst Lange, our Executive Vice President and Chief Scientific Officer, reflect on our findings and news from this week. Our company announcement can be found here https://lnkd.in/d_JZMXyz #PRESS

4 in 5 teens living with obesity will grow up to be adults with obesity. What if we could stop the disease before it starts? As part of our Cities for Better Health programme, we’re co-designing, implementing, and evaluating childhood obesity prevention solutions in 6 cities around the world – each tailored to local communities.

All children deserve the chance to grow up healthy, right? Heavy exposure to unhealthy food options and fewer places to play mean too many kids face overweight or obesity. This World Children’s Day, we’re highlighting our work with partners around the world to prevent childhood obesity. Together we can build healthier futures: https://lnkd.in/e9_dnZX #WorldChildrensDay UNICEF

Fake medicine is a growing problem. Nearly 95% of online pharmacies selling these are operating illegally. Understanding the risks is the first step toward avoiding them. Your health is too important to risk using fake medicines. Learn more here: https://lnkd.in/dcnmsfnX #PatientSafety

This World Diabetes Day, we’re proud to announce a five-year extension of our partnership with Team Novo Nordisk!    Together, we're continuing our shared mission to drive change for people living with diabetes worldwide 💙   Learn more about our partnership here www.novonordisk.com

City Health Talk webinar – Cycling for healthier and more sustainable neighbourhoods Around the world, grassroots innovators are showing that the simple act of cycling can transform daily life – improving health, advancing equity and strengthening communities. To spotlight and scale these ideas, Cities for Better Health and the European Cyclists' Federation (ECF) launched the Healthy Cycling Challenge. From over 240 submissions across 46 countries, three winning projects have been selected for their impact in breaking down barriers to cycling and reimagining urban mobility. Join Jo Jewell (Cities for Better Health) and Laurianne Krid (ECF) on 10 December (14.00-15.00 CET) for a City Health Talk webinar to meet the winners and discover how they are inspiring healthier, more inclusive cities: 🇧🇷 Community bike-sharing systems in favelas in São Paulo (Instituto Caminhabilidade) 🇵🇪 Urban cycling for healthier and more inclusive cities in Peru (Peruvian Society for Environmental Law) 🇳🇵 Community learning on wheels in Nepal (Cycle City Network Nepal) Don’t miss this opportunity to be inspired by the power of cycling. Learn more about the Healthy Cycling Challenge winners: https://lnkd.in/dMT-QG-P

Picture Central Park in New York. Now multiply it by 50. That’s the amount of farmland needed each year to grow the wheat and maize used to produce our medicines 🌾   We’re partnering with suppliers who support regenerative farming methods as part of the solution to halt the loss of nature in our value chain.   For better: • Soil health • Planet health • Human health Read more here: https://lnkd.in/dv3z-xFK #COP30

Our new data presented at The Liver Meeting® 2025 shows that semaglutide injection was associated with liver health-related benefits across a spectrum of weight loss thresholds in people living with MASH. Learn more in the press release here https://lnkd.in/d3-5qF_4 #PRESS

Our new data presented at ObesityWeek® 2025 shows that CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease. Learn more in the press release https://lnkd.in/dQNna2RJ #PRESS

We announced an agreement to expand access to our GLP-1 treatments for millions of Americans living with obesity and diabetes. This reinforces our ongoing commitment to advancing innovative, affordable options for patients. Learn more in the company announcement here https://lnkd.in/dkzh9kcR #PRESS

We are presenting new semaglutide data showing the relevance of BMI and waist targets in lowering risk of obesity-related complications at ObesityWeek® 2025. Learn more in the press release here https://lnkd.in/d6RkdrWa #PRESS

We’re presenting new data on oral semaglutide and its demonstrated reduction in cardiovascular risk factors for people living with obesity at ObesityWeek® 2025. Learn more in the press release here https://lnkd.in/d7S7S5xJ #PRESS

Our results for the first nine months of 2025 are out.   Hear the reflections from our CEO Mike Doustdar and learn more in the company announcement here https://lnkd.in/dpZJRdqJ #PRESS

Did you know type 2 diabetes affects more than blood sugar? Learn why it’s important to protect your heart, kidneys and liver – for a healthier future free from complications 💙 #DiabetesAwarenessMonth

For women in menopause, the risk of obesity and cardiovascular disease increases.   Advancing research, awareness and solutions could support women in living healthier lives during this transition.

We’re presenting new data in oral semaglutide in obesity and pipeline at ObesityWeek® 2025.   Learn more in the press release here www.novonordisk.com #PRESS

📣 “Why are we shouting again?!” During menopause, a lot changes - including a higher risk of obesity and heart disease. It’s time to talk about it. #MenopauseDay

Do hormones play a role in driving obesity in the female body? Yes – more than you might think. What else do you want to know about obesity? Let us know in the comments 👇 #UnordinaryDrivesChange

Novo Nordisk and Omeros Corporation announce asset purchase and license agreement for Omeros’ clinical-stage candidate for rare blood and kidney diseases. Learn more in our press release 👉 https://lnkd.in/dcXwhwc4   #PRESS

We are announcing an agreement with Akero Therapeutics to acquire the company and its promising candidate in phase 3 development for metabolic dysfunction-associated steatohepatitis (MASH).   The acquisition reflects our long-term strategy to develop innovative and differentiated medicines and treat millions of more people living with diabetes, obesity and their associated comorbidities.   You can read more in the company announcement here: https://lnkd.in/gu4MH2U

In case you didn’t know… 👉 Cardiovascular disease is the number one cause of death in people with obesity, and those impacted by the serious liver disease MASH 👉People living with type 2 diabetes are up to 4x as likely to have a heart attack 👉Up to half of people with chronic kidney disease have cardiovascular disease

Obesity, type 2 diabetes, liver disease, kidney problems – they're all connected. And at the centre? The heart ❤️ Seeing the whole picture means earlier detection, better care, better outcomes. #WorldHeartDay

Did you know that Alzheimer’s disease affects around 100 million people globally? While its impact on memory, decision-making, and independence is significant, there is still much to uncover about how underlying health factors like neuroinflammation influence the progression of this disease. Vote below or share your thoughts in the comment👇 #WorldAlzheimersDay

Back at #EASD2025 in Vienna!   This week our CEO Mike Doustdar was back in his hometown Vienna visiting the European Association for the Study of Diabetes e.V. (EASD). Since 1965, we have been part of this important conference where cutting edge science brings together everyone who are passionate about treating and curing diabetes and obesity. 

New findings from a head-to-head real-world study exploring cardiovascular events for people with type 2 diabetes shared at the European Association for the Study of Diabetes #EASD2025. Learn more in our press release here https://lnkd.in/gu4MH2U #PRESS

We are publishing phase 3 data on our obesity oral product in The New England Journal of Medicine. This data provides a foundation for our ambition to offer a pill for weight management. Learn more in our press release here www.novonordisk.com #PRESS 

What's the science behind the weight-loss headlines? You’ve maybe heard about GLP-1 and semaglutide, but how do they work in the body? And what's the difference between the two? Get the facts in this video 👇

We are sharing phase 3 data from our obesity pipeline and plans for future research at the European Association for the Study of Diabetes Congress #EASD2025. We are committed to continuing to innovate for people with obesity. Read more in our press release here www.novonordisk.com #PRESS

We are sharing real-world obesity product data on food noise and mental wellbeing at the European Association for the Study of Diabetes Congress #EASD2025. Food noise – unwanted and intrusive thoughts about food – can affect the quality of life and weight loss efforts of people living with obesity. Learn more in our press release here https://lnkd.in/gu4MH2U #PRESS

What is food noise? Discover how food noise can disrupt daily life for people living with overweight or obesity.

Key regulatory milestone achieved as the first oral GLP-1 RA receives EU approval for cardiovascular benefits in type 2 diabetes. Learn more in our press release here www.novonordisk.com #PRESS

We are announcing a company-wide transformation plan to simplify our organisation, improve speed of decision-making and reallocate resources towards our company’s growth opportunities in diabetes and obesity. As part of this, all business areas and regions are being assessed, with the intention to simplify structures, reduce duplication, and sharpen focus.   Our CEO Mike Doustdar, says: “We are convinced that this is the right thing to do for the long-term success of Novo Nordisk. We need a shift in our mindset and approach so we can be faster and more agile. Our transformation plan is designed to deliver this.” You can read more in the company announcement here https://lnkd.in/gu4MH2U

New data on food noise, body composition and cardiovascular benefits, as well as pipeline data is being presented at the European Association for the Study of Diabetes Congress #EASD2025. Learn more in the press release here www.novonordisk.com #PRESS

Ever wondered what a day in the lab looks like for a Senior Scientist? 👀 Step into our obesity research lab and discover how our scientists (and their samples) are shaping the future of medicine. #UnordinaryDrivesChange

We have news to share: Findings from a real-world study for people living with obesity and cardiovascular disease are being shared at the European Society of Cardiology Congress #ESC2025. Learn more in the press release here www.novonordisk.com

Cardiovascular disease is the leading cause of mortality worldwide and is closely linked to metabolic conditions. Understanding these connections is key to better prevention and care. Vote below or add your thoughts in the comments 👇 #ESC2025

Looking back at our obesity research milestones from 1996 to today, it struck us: Behind every breakthrough, there's a story of persistence, curiosity, and sometimes unexpected discoveries. #UnordinaryDrivesChange

You can't fit 25+ years of obesity research into a LinkedIn post, but we've tried. Today, we're still dedicated to delivering scientific breakthroughs in the treatment of obesity and making a positive impact on one of the greatest healthcare challenges of our time. #UnordinaryDrivesChange

By 2035, 3.3 billion adults are projected to live with overweight or obesity. Tackling this global societal problem requires urgent action. But where to start? Let us know what you think 👇

The numbers are staggering. Behind each statistic are people waiting for innovations that could change their life. We’re on it. Continuing to deliver solutions at the speed and scale the world needs, for long-term health. Learn how we continue to innovate to defeat obesity: https://lnkd.in/eCyWpsQ #UnordinaryDrivesChange

Can you pursue your sport at the highest level while living with type 1 diabetes? Bailey McDonald from Team Novo Nordisk sets the record straight about what it’s like to be a pro cyclist living with type 1 diabetes. Did any of these myths or facts surprise you? Comment below👇   #UnordinaryDrivesChange

Our CEO Mike Doustdar chose the US as his first international trip since taking the helm – and it was a homecoming.   As Mike spent most of his formative years growing up in Ohio, visiting our largest market was both professional and personal.   "The US isn’t just important to Novo Nordisk - it also holds a special place in my heart... It was where I got the nickname “Mike”, and where I learned the value of hard work and entrepreneurial spirit that has stayed with me ever since," he says.    The US is where we serve 10+ million Americans through 12 locations across 9 states, powered by 10,000+ dedicated employees.   Mike spent time with our Executive Vice President Dave Moore and many of our US colleagues, and got to experience their commitment to patients - and their passion, excitement and focus on strengthening our leadership in diabetes and obesity.

"You have type 1 diabetes.”   When pro cyclist Bailey McDonald heard these words, he had to dig deep. He found strength in his new team, his community, and within himself.   A little more than a year after his diagnosis, Bailey is now pushing limits as a pro athlete for Team Novo Nordisk. Inspiring us to keep driving change in diabetes innovation - like we have been for more than a century 💙   #UnordinaryDrivesChange

Welcome, Mike Doustdar - our 6th CEO!   With 30+ years of company experience, Mike brings a track record of growth and high performing teams within Novo Nordisk.   "I'm a forever-optimist when it comes to Novo Nordisk. I see multiple growth drivers and a company that can accelerate its positive impact on the world."   Time to write our next chapter.